CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression

Published:2016-01-24 Issue:8 Volume:7 Page:9069-9083
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Mitra Partha¹,Yang Ren-Ming¹,Sutton James²,Ramsay Robert G.³⁴,Gonda Thomas J.¹

Affiliation:

1. School of Pharmacy, University of Queensland, Brisbane, QLD, Australia

2. Novartis Institute for Biomedical Research, Emeryville, CA, USA

3. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

4. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK9 inhibitors for the treatment of solid tumors;Biochemical Pharmacology;2024-11

2. Emerging role of MYB transcription factors in cancer drug resistance;Cancer Drug Resistance;2024-04-30

3. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers;Cancer Research;2023-10-06

4. Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies;Molecules;2023-05-23

5. Synthetic oleanane triterpenoids suppress MYB oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy;Frontiers in Oncology;2023-04-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP